Description

Monoprost Eye Drops Solution 50 mcg/ml, Sachet №30

Ingredients:

Monoprost eye drops contain 50 mcg/ml of latanoprost as the active ingredient. Other ingredients include benzalkonium chloride, sodium dihydrogen phosphate monohydrate, disodium hydrogen phosphate anhydrous, and water for injections.

Dosage:

The recommended dosage is one drop in the affected eye(s) once daily in the evening. Do not exceed the prescribed dosage as it may increase the risk of side effects.

Indications:

Monoprost eye drops are indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Contraindications:

Do not use Monoprost eye drops if you are allergic to any of the ingredients. It is also contraindicated in patients under 18 years of age unless specifically instructed by a healthcare provider.

Directions:

To administer the eye drops, wash your hands before use. Tilt your head back, pull down the lower eyelid, and instill the prescribed number of drops. Close your eyes for a few minutes without blinking.

Scientific Evidence:

Studies have shown that latanoprost, the active ingredient in Monoprost eye drops, effectively lowers intraocular pressure by increasing the outflow of aqueous humor from the eye. Research published in the Journal of Ocular Pharmacology and Therapeutics demonstrated the efficacy of latanoprost in reducing intraocular pressure in patients with glaucoma.

Additional Information:

It is important to store Monoprost eye drops at room temperature away from light and moisture. Keep the single-dose sachets in the original packaging until ready to use to protect them from contamination.

Pharmacological Effects:

Latanoprost works by increasing the drainage of fluid from the eye, thereby reducing intraocular pressure. This mechanism of action helps in preventing optic nerve damage and vision loss associated with conditions like glaucoma.

Clinical Trials:

In a comparative study published in the British Journal of Ophthalmology, latanoprost was found to be more effective in reducing intraocular pressure compared to timolol, a beta-blocker commonly used in glaucoma treatment. The study concluded that latanoprost is a valuable option for patients requiring additional intraocular pressure reduction.